Genetic variants in <i>PDSS1</i> and <i>SLC16A6</i> of the ketone body metabolic pathway predict cutaneous melanoma‐specific survival

Dai, Wei; Liu, Hongliang; Chen, Ka; Xu, Xinyuan; Qian, Danwen; Luo, Sheng; Amos, Christopher I.; Lee, Jeffrey E.; Li, Xin; Nan, Hongmei; Li, Chunying; Wei, Qingyi

doi:10.1002/mc.23191

Cited by 10 publications

(6 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A multicenter study found that SLC16A5 gene mutation was associated with adverse reactions to platinum-based drugs in testicular cancer patients, which provided a reference for the mechanism of adverse reactions in testicular cancer [ 46 ]. Wei et al found that upregulation of SLC16A6 affects patient outcomes through ketone body transporter pathways [ 47 ]. Studies of SLC16A7 have focused on prostate cancer and are associated with the malignant transformation of prostate cancer cells [ 48 ].…”

Section: Discussionmentioning

confidence: 99%

A pan-cancer analysis revealed the role of the SLC16 family in cancer

Xie

et al. 2021

Channels

View full text Add to dashboard Cite

Cancer is one of the serious diseases that endanger human health and bring a heavy burden to world economic development. Although the current targeted therapy and immunotherapy have achieved initial results, the emergence of drug resistance shows that the existing research is far from enough. In recent years, the tumor microenvironment has been found to be an important condition for tumor development and has profound research value. The SLC16 family is a group of monocarboxylic acid transporters involved in cancer metabolism and the formation of the tumor microenvironment. However, there have been no generalized cancer studies in the SLC16 family. In this study, we conducted a pan-cancer analysis of the SLC16 family. The results showed that multiple members of the SLC16 family could be used as prognostic indicators for many tumors, and were associated with immune invasion and tumor stem cells. Therefore, the SLC16 family has extensive exploration value in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

A pan-cancer analysis revealed the role of the SLC16 family in cancer

Xie

et al. 2021

Channels

View full text Add to dashboard Cite

show abstract

“…Several biomarkers or techniques detecting specific chromosomal sequence abnormalities have been proposed for melanoma susceptibility, prognosis, and recurrence. These include SNPs of metabolic pathway genes [4], CD28/CTL4/ICOS genes [5], the Tyrosinase gene [6], VDR genes [7], and PI3K genes [8]. This has allowed the definition of several SNP signatures for melanoma prognosis [9,10].…”

Section: Introductionmentioning

confidence: 99%

Plasma Thermogram Parameters Differentiate Status and Overall Survival of Melanoma Patients

et al. 2023

View full text Add to dashboard Cite

Melanoma is the fifth most common cancer in the United States and the deadliest of all skin cancers. Even with recent advancements in treatment, there is still a 13% two-year recurrence rate, with approximately 30% of recurrences being distant metastases. Identifying patients at high risk for recurrence or advanced disease is critical for optimal clinical decision-making. Currently, there is substantial variability in the selection of screening tests and imaging, with most modalities characterized by relatively low accuracy. In the current study, we built upon a preliminary examination of differential scanning calorimetry (DSC) in the melanoma setting to examine its utility for diagnostic and prognostic assessment. Using regression analysis, we found that selected DSC profile (thermogram) parameters were useful for differentiation between melanoma patients and healthy controls, with more complex models distinguishing melanoma patients with no evidence of disease from patients with active disease. Thermogram features contributing to the third principal component (PC3) were useful for differentiation between controls and melanoma patients, and Cox proportional hazards regression analysis indicated that PC3 was useful for predicting the overall survival of active melanoma patients. With the further development and optimization of the classification method, DSC could complement current diagnostic strategies to improve screening, diagnosis, and prognosis of melanoma patients.

show abstract

“… 5 Several studies showed that PDSS1 speed up the progression of some tumors, such as cutaneous melanoma, bladder cancer, breast cancer, and HCC. 6–11 Bioinformatics studies suggest that PDSS1 may be associated with hypoxia in the tumor microenvironment of HCC. 9–11 However, it is not yet clear whether PDSS1 acts as a prognostic marker in HCC and if its expression is related to the tumor immune infiltration.…”

Section: Introductionmentioning

confidence: 99%

Decaprenyl Diphosphate Synthase Subunit 1 (PDSS1): A Potential Prognostic Biomarker and Immunotherapy-Target for Hepatocellular Carcinoma

Yang¹,

Li²,

Tang³

et al. 2022

CMAR

View full text Add to dashboard Cite

Purpose PDSS1 (decaprenyl diphosphate synthase subunit 1) plays an important role in the progression of several types of tumor. However, the biological functions of PDSS1 remain unclear in patients with hepatocellular carcinoma (HCC). In this study, We attempted to determine the role of PDSS1 in predicting the survival and efficacy of immunotherapy for HCC patients. Methods We analyzed the expression of PDSS1 in pan-cancer by Tumor Immune Estimation Resource (TIMER) and UALCAN database. Next, we investigated the correlations between the expression and potential prognostic value of PDSS1 in pan-cancer by Gene Expression Profiling Interactive Analysis (GEPIA) and Kaplan-Meier plotter and further confirmed our finding in our study of 139 patients with HCC. Furthermore, we correlated expression patterns with the presence of immune cell infiltrates and immune regulatory molecules in HCC tissue by TIMER. Finally, its potential immune-related mechanism was explored by Gene Set Enrichment Analysis (GSEA). Results Multiple datasets demonstrate that PDSS1 is up-regulated in HCC tissues compared with adjacent tissues, which was validated at mRNA (databases) and protein levels (our cohort). Patients with higher PDSS1 expression had shorter overall survival and relapse-free survival. In addition, PDSS1 expression was positively related to early recurrence and served as an independent poor prognostic factor for HCC. Patients with higher PDSS1 expression had lower CD8+ T cells in HCC tissue, and PDSS1 deteriorates T cell exhaustion by promoting T cell surface inhibitory receptors’ secretion and immunosuppressive cell proliferation. Furthermore, PDSS1 was positively correlated with the WNT, TGFβ, VEGF, and other signaling pathways in HCC. Conclusion PDSS1 is a potential prognostic biomarker and immunotherapy target for hepatocellular carcinoma.

show abstract

Genetic variants in PDSS1 and SLC16A6 of the ketone body metabolic pathway predict cutaneous melanoma‐specific survival

Cited by 10 publications

References 42 publications

A pan-cancer analysis revealed the role of the SLC16 family in cancer

A pan-cancer analysis revealed the role of the SLC16 family in cancer

Plasma Thermogram Parameters Differentiate Status and Overall Survival of Melanoma Patients

Decaprenyl Diphosphate Synthase Subunit 1 (PDSS1): A Potential Prognostic Biomarker and Immunotherapy-Target for Hepatocellular Carcinoma

Contact Info

Product

Resources

About